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ABSTRACT: An expeditious isolation method for the cembrane diterpene
alcohols incensol (1a) and serratol (2) has been developed from respectively
African and Indian frankincense. The two native alcohols and a series of
semisynthetic derivatives of incensol were evaluated for transient receptor
potential vanilloid 3 (TRPV3) activation and the inhibition of NF-κB, the
putative molecular targets underlying the psychotropic and anti-inflammatory
activities of incensol acetate (IA, 1b). Serratol (2) was the most potent TRPV3
activator, outperforming by 2 orders of magnitude the reference agonist
thymol and by 1 order of magnitude incensol acetate (1b). Acylation,
epimerization, and oxidation did not significantly improve the affinity of
incensol for TRPV3, while NF-κB inhibition, marginal for both natural
alcohols, could be improved by esterification of incensol (1a) with lipophilic
acids. Interestingly, incensol (1a) but not IA (1b) was a potent inhibitor of
STAT3, raising the possibility that hydrolysis to incensol (1a) might be involved in the in vivo biological activity of IA (1b).
Serratol was not amenable to chemical modification, but some marine cembranoids related to the frankincense diterpenoids
showed a certain degree of TRPV3-activating properties, qualifying the aliphatic macrocyclic cembrane skeleton as a selective
chemotype to explore the pharmacology of TRPV3, a thermo-TRP otherwise resistant to modulation by small molecules.
Cembranes are a biogenetically early class of diterpenoidsfor which their distribution in Nature encompasses
marine invertebrates, lower and higher plants, and insects.1
Accumulation of cembranes is, however, rare. Within marine
organisms it is limited to soft corals and, to a lesser extent, to
sponges, while some conifer resins, frankincense, and tobacco
are the major sources of cembranes within terrestrial plants.
The first member of the class was structurally elucidated in
1962,2 but interest in plant cembranes has long been limited to
the realm of perfumery, since these compounds are important
constituents of the essential oil from frankincense and
contribute, with a resinous and woody note, to its sensory
properties.3 More recently, incensol4 acetate (IA, 1b), a
constituent of both African [Boswellia papyrifera Hochst., B.
carteri Birdw. (Burseraceae)] and Arabian (B. sacra Flueck.)
frankincense,5 was identified as a potent activator of transient
receptor potential vanilloid 3 (TRPV3),6 a heat-sensitive ion
channel highly expressed in keratinocytes and involved in skin
heat sensitivity and thermoregulation.6 TRPV3 is also expressed
in the central nervous system (CNS),7 and, using IA as a probe,
its activation was associated with anxiolytic and antidepressant
activity.6 More recently, downregulation of the expression of
TRPV3 in adipocytes was discovered to play a critical role in
the accumulation of visceral fat.8
As an ester of an aliphatic macrocyclic alcohol, IA is a
surprising agonist for TRPV3, for which the archetypal ligands
are aromatic phenolics such as carvacrol and thymol from
thyme, eugenol from clove,7 and the phytocannabinoid
cannabidiol and tetrahydrocannabivarin.9 A few oxygenated
monoterpenes, including camphor and eucalyptol have been
reported to show a modest affinity for TRPV3,10 but these
compounds, as well as the phenolic TRPV3 agonists, are
promiscuous in terms of affinity for thermo-TRPs, targeting
also other members of this class of ion channels.9,10 Conversely,
IA did not show any significant affinity for other thermo-TRPs
as well as for various receptors and ion channels of relevance
for drug discovery.6 Owing to its potency and selectivity, IA
qualifies therefore as a unique ligand to investigate the function
and the modulation of TRPV3, for which recent studies have
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suggested has broad physiological implications, from human
genetic diseases to inflammation, skin physiology, weight
management, and brain function.7 Interestingly, resurrection
and functional testing of woolly mammoth tissues have shown
that a mutation of TRPV3 was critical for their adaptation to
cold, highlighting the evolutionary relevance of this thermo-
sensor.11
Despite the interest for incensol acetate (1b) as a TRPV3
ligand, no structure−activity study has so far been carried out
on this compound, and the activity of its closely related
analogue serratol (2) from Indian frankincense (B. serrata
Roxb. ex Colebr.)12 is still unknown. Capitalizing on the
development of an expeditious method for the isolation of
incensol and serratol from commercial frankincense, we have
explored the biological space around the cembrane chemotype
of TRPV3 activators. Since IA shows in vivo neuroprotective
properties13 possibly associated with inhibition of NF-κB,14 the
interaction with this pro-inflammatory transcription factor was
also evaluated.
■ RESULTS AND DISCUSSION
African frankincense contains a mixture of incensol (1a), a
secondary alcohol, and its acetate (1b), while Indian
frankincense contains the tertiary alcohol serratol (2).15 The
purification of the cembrane alcohols was easier than that of IA
(1b), and therefore, it was found more convenient to synthesize
IA (1b) from incensol rather than obtaining it by direct
isolation. In practice, powdered, frozen African frankincense
was extracted with petroleum ether, and, after filtration on
neutral alumina to remove the acidic constituents and
evaporation, the neutral extract was treated with LiAlH4 in
THF to reductively cleave the acetate group, which was
otherwise sluggish to remove by hydrolysis. After acidic workup
and extraction with EtOAc, the residue was purified by gravity
column chromatography (CC) on silica gel, affording incensol
(1a) in a yield of ca. 3.9% on the commercial gum resin. A
similar protocol was used for serratol, omitting, however, the
treatment with LiAlH4.
Incensol was acylated to explore issues such as elongation of
the alkyl chain (nonanoyl ester, 1c), its aromatization (benzoyl
ester, 1d), and a combination of the two maneuvers
(phenylacetate and cinnamate esters, 1e and 1f, respectively).
The choice of these acids was inspired by previous studies on
the acylative modification of polyol templates for the
modulation of thermo-TRPs.16 Serratol, a tertiary alcohol,
proved resistant to acylation under a variety of protocols. Next,
the epoxidation of the endocyclic double bonds of the natural
polyols was investigated. Incensol afforded a crystalline
monoepoxide by treatment with peracids17 and was then
acetylated to the acetate 3b. Conversely, the epoxidation of
incensol acetate was not chemoselective, affording a mixture of
two regioisomeric epoxides (3b and 4), separated by gravity
CC and identified by comparison with the literature
spectroscopic data.17b The reason for the different chemo-
selectivity associated with the epoxidation of the alcohol 1a and
its acetate 1b is unclear and is seemingly associated with
different conformational properties between the two com-
pounds. The epoxidation of serratol, also under buffered
conditions, gave a complex mixture from which no pure
compound could be obtained. Finally, incensol (1a) was
oxidized to the ketone 5 (incensone), for which reduction gave
a mixture of incensol (1a) and epi-incensol (6).17a
The 12 cembranes 1a,f−6 were evaluated for their
interaction with TRPV3. This ion channel shows 43% sequence
homology with TRPV1 but has a distinct pharmacology.7 Thus,
while TRPV1 is activated by burning heat (>42 °C), TRPV3
has a lower thermal threshold (>33 °C), corresponding to a
feeling of mild warmth,18 and its activation should, in principle,
be devoid of the painful side-effects typical of TRPV1 agonists.
Furthermore, while activation of thermo-TRPs such as TRPA1,
TRPV1, and TRPV4 is characterized by desensitization, the
repeated thermal or chemical stimulation of TRPV3 is instead
associated with sensitization, leading to an increase of activity
and larger excitatory signals.19 While there is no shortage of
interest in the pharmacological modulation of TRPV3 for
conditions such as inflammatory skin disorders, itch, pain
sensation, hypothermia, obesity, and depression,7 this ion
channel has proved rather difficult to modulate with small
molecules, and the ligands described so far are promiscuous,
also targeting other thermo-TRPs [2-aminoethoxydiphenyl
borate (2-APB), camphor, eugenol, thymol] as well as
unrelated nonion channel targets (phytocannabinoids).7 It
was therefore important to explore the chemical space around
IA (1b), the only selective TRPV3 agonist identified so far.
TRPV3 activity was evaluated in rTRPV3-expressing HEK293
cells sensitized with the agonist 2-APB (100 μM). IA stimulated
TRPV3-mediated calcium influx with high efficacy (43.4 ±
1.9% of the effect of 4 μM ionomycin) and potency (EC50 1.4
± 0.2 μM) (Table 1). The EC50 value observed in rTRPV3 was
lower than that reported for mTRPV3 (16 μM),6 suggesting a
higher sensitivity to IA (1b) for the rat orthologue. Removal of
the acetate (incensol, 1a), and oxidation to incensone (5) had
only a modest effect on potency, as evaluated by EC50, while an
increase of efficacy (65.1 ± 1.1% of 4 μM ionomycin) was
surprisingly observed for incensol. Conversely, epimerization to
epi-incensol (6) and epoxidation to the 3- and 7-epoxides (3b
and 4, respectively) caused a decrease in potency and efficacy,
as did the replacement of the acetate by a cinnamate (1f). The
decrease of activity was lower for the benzoate 1d and the
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nonanoate 1c, while the phenylacetate 1e showed similar
potency, but decreased efficacy (25.6 ± 0.6% of 4 μM
ionomycin), compared to IA (1b).
The two cembranes sarcophytoxide (7)20 and sarcophine
(8),21 the major constituents of the Indonesian soft coral
Sarcophyton sp. (order Alcyonacea, family Alcyoniidae), were
also investigated for TRPV3-activation properties. Interestingly,
these marine cembranes also showed significant TRPV3-
activating properties, although at least 1 order of magnitude
lower than IA (1b). In contrast, the tertiary cembrane alcohol
serratol (2) was 1 order of magnitude more potent than IA and
represents the first submicromolar TRPV3 agonist described to
date. Serratol outperformed IA also in terms of efficacy,
evaluated as maximal activation with 4 μM ionomycin (62.4 ±
1.0%), a value similar to the one measured for incensol (65.1 ±
1.1%).
The submicromolar affinity of serratol (2) for TRPV3 is
surprising, since this compound has only one polar group and is
otherwise hydrophobic. Strong intermolecular interactions are
associated with the presence of polar groups, and the activity of
2 on TRPV3 is somewhat reminiscent of that of the
hydrocarbon caryophyllene on the cannabinoid receptor
CB2.
22 The medium-sized hydrophobic ring of caryophyllene
can adopt more than one conformation,23 and an even higher
number of geometries is possible for serratol, complicating the
definition of a pharmacophoric model.24
IA (1b) has been shown to inhibit NF-κB activation, but the
reported IC50 value in vitro (over 100 μM)
14 suggests a
marginal activity, unlikely to significantly contribute to the
neuroprotective activity observed in vivo.13 Nevertheless, it was
interesting to investigate the effect of cembranes on NF-κB
activation, since incensol acetate could be rapidly deacetylated
in vivo, and incensol itself could show higher potency. In any
event, incensol and, with the exception of 1e and 1c, also its
esters and analogues showed only marginal, if any, activity on
TNFα-induced NF-κB activation (IC50 > 50 μM), casting
doubts on the involvement of NF-κB in the in vivo activity of
IA against neuroinflammation. On the other hand, incensol
(1a), but not IA (1b), showed potent inhibitory activity on IL-
6-induced STAT3 activation (IC50 = 15.8 ± 2.88 μM), and,
given the relevance of STAT3 in neuro-inflammation,25 it does
not seem unrealistic to assume its involvements, secondary to
enzymatic deacetylation, in the in vivo neuroprotective activity
of IA (1b). The nonanoate and the phenylacetate esters of
incensol (1c and 1e, respectively) showed a significant
inhibitory activity on NF-κB activation (Table 1), an interesting
observation, since, unlike most NF-κB inhibitors, these
compounds are devoid of electrophilicity and redox proper-
ties.14 Furthermore, incensol nonanoate (1c) also inhibited
STAT3 (IC50 = 38.7 ± 3.99 μM), while all the other analogues
were inactive. Taken together, these observations suggest that
the cembrane structural motif is an interesting platform for the
noncovalent inhibition of transcriptions factors involved in
inflammation, as exemplified by incensol (1a) and its
nonanoate ester (1c), which could inhibit the activity of both
NF-κB and STAT3.
The macrocyclic cembrane skeleton is also a privileged
structure for targeting TRPV3 and evaluating the pharmaco-
logical potential of its modulation. Of special relevance is the
identification of serratol (2) as a submicromolar agonist of
TRPV3, although we were unable to derivatize this compound
without obtaining complex mixtures requiring challenging
chromatographic resolution. The in vivo evaluation of the
neuroprotective activity of the phenolic monoterpene carvacrol
to demonstrate the druggability of TRPV3 by small molecules
gave unclear results due to the low potency of this agonist and
its pleiotropic profile of activity.25 Cembrane ligands such as IA
(1b) and serratol (2) qualify as better probes because of their
higher potency and, at least for IA and possibly also for serratol,
selectivity within the TRP ion channel family and should be
Table 1. Evaluation of the Cembranes 1a,f−8 on Calcium Influx in HEK293 Cells Transfected with rTRPV3 and Sensitized with
2-APBa and in NF-κBb and STAT3c Transcriptional Activities
compound efficacy TRPV3 (% ionomycin 4 μM) potency EC50 TRPV3 μM IC50 TRPV3 μM (thymol 100 μM) IC50 NF-κB (STAT3) (μM)
1a 65.1 ± 1.1 2.1 ± 0.2 2.1 ± 0.1 >50 (15.84 ± 2.88)
1b 43.4 ± 1.9 1.4 ± 0.2 2.2 ± 0.5 >50 (>50)
1c 35.4 ± 0.9 5.6 ± 0.8 24.1 ± 1.9 35.5 ± 1.1 (38.66 ± 3.99)
1d 10.3 ± 0.9 4.4 ± 1.1 >100 >50 (>50)
1e 25.6 ± 0.6 1.2 ± 0.2 21.7 ± 3.1 22.4 ± 2.4 (>50)
1f 14.1 ± 0.4 10.5 ± 1.5 94.4 ± 8.6 >50 (>50)
2 62.4 ± 1.0 0.17 ± 0.01 0.15 ± 0.01 >50 (>50)
3a 27.2 ± 1.0 25.4 ± 0.2 >100 >50 (>50)
3b 57.7 ± 2.3 8.8 ± 0.5 13.2 ± 1.2 >50 (>50)
4 31.6 ± 0.6 8.6 ± 0.4 21.1 ± 1.7 >50 (>50)
5 46.5 ± 0.6 2.4 ± 0.2 5.8 ± 0.6 >50 (>50)
6 38.0 ± 1.1 7.3 ± 0.3 12.3 ± 0.4 >50 (>50)
7 30.0 ± 2.4 29.2 ± 2.1 57.5 ± 4.9 >50 (>50)
8 21.3 ± 0.7 30.1 ± 3.8 >100 >50 (>50)
thymol 49.4 ± 0.9 29.0 ± 0.5
SC415 7.9 ± 0.6
aTRPV3-epressing HEK293 cells were first sensitized with the structurally unrelated agonist 2-aminoethoxydiphenyl borate (100 μM). bNIH-3T3-
KBF-Luc cells were preincubated with the compounds for 15 min, then stimulated with TNFα for 6 h, and luciferase activity was measured in the cell
lysates. cHeLa-STAT3-Luc cells were preincubated with the compounds for 15 min, then stimulated with INFγ for 6 h, and luciferase activity was
measured in the cell lysates.
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seriously considered for the in vivo investigation of the
physiological role of TRPV3. Conversely, incensol (1a) seems
an excellent candidate for neuroprotection, due to its
pleiotropic mechanism of activity that includes, apart from
the modulation of TRPV3, also the inhibition of the pro-
inflammatory transcription factor STAT3.
The simple purification method developed in this inves-
tigation makes it possible to obtain incensol (1a) and serratol
(2) from frankincense, an easily available biomass,26 in amounts
sufficient to sustain a systematic exploration of the biological
space around the cembrane chemotype and for in vivo studies.
Furthermore, the occurrence of a host of polar minor
cembranoids in frankincense27 will make it possible to extend
this exploration also to areas of the pharmacophoric space
unaccessible by chemical modification of the natural products
but populated by naturally occurring analogues.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations (CHCl3)
were measured at 589 nm on a P2000 JASCO polarimeter. IR spectra
were registered on an Avatar 370 FT-IR Techno-Nicolet apparatus. 1H
(500 and 400 MHz) and 13C (125 and 100 MHz) NMR spectra were
measured on Varian INOVA NMR spectrometers. Chemical shifts
were referenced to the residual solvent signal (CDCl3: δH = 7.26, δC =
77.0). Homonuclear 1H connectivities were determined by the COSY
experiment. One-bond heteronuclear 1H−13C connectivities were
determined with the HSQC experiment. Two- and three-bond
1H−13C connectivities were determined by gradient 2D HMBC
experiments optimized for a 2,3J = 9 Hz. Low- and high-resolution
ESIMS were obtained on an LTQ OrbitrapXL (Thermo Scientific)
mass spectrometer.
Silica gel 60 (70−230 mesh) used for gravity column chromatog-
raphy was purchased from Macherey-Nagel. Reactions were monitored
by TLC on Merck 60 F254 (0.25 mm) plates, visualized by staining
with 5% H2SO4 in ethanol and heating. Organic phases were dried
with Na2SO4 before evaporation. Chemical reagents and solvents were
from Aldrich and were used without any further purification unless
stated otherwise.
Plant Material. Boswellia serrata and B. papyrifera were purchased
from Anbesa (Mestre, VE, Italy). The identity of the material was
checked by TLC according to the method reported by Jauch and co-
workers, with caryophyllene oxide, oxotirucallic acid, incensol, incensol
acetate, and serratol as reference compounds.15 The profile of
occurrence/absence of these compounds matched that proposed for
their differentiation, as did the odor of the extracts (“lemony” for B.
papyrifera, “pine-like” for B. serrata).15 A voucher specimen of the resin
batch used in this investigation is kept at the laboratory in Novara for
both B. papyrifera (2016-1) and B. serrata (2016-2).
Isolation of Incensol (1a). A sample (40.8 g) of B. papyrifera resin
was cooled in a freezer at −18 °C for 3 h and then powered using a
kitchen blender. The frozen powder was extracted twice with 400 mL
of petroleum ether (ratio resin:solvent 1:10), affording, after filtration
and evaporation, 13 g of a pale yellow oil with a lemon-like odor. The
latter was dissolved in the minimal amount of petroleum ether and
then vacuum-filtered over neutral alumina (40 g, ratio oil:stationary
phase 1:3, elution volume: 300 mL) to remove acidic constituents.
Removal of the solvent gave 4.19 g (10.3%) of an orange-odor oil,
which was dissolved in dry THF (50 mL) and treated with an excess of
freshly powdered LiAlH4 (1.24 g, ca. 300 mg/g of crude purified
fraction). After stirring under nitrogen for 12 h at room temperature,
the reaction was worked up by the addition of EtOAc to quench the
excess of LiAlH4 and then with 2 N H2SO4 to hydrolyze the aluminate
salts. Extraction with EtOAc afforded 3.9 g of an oil, which was
purified by gravity CC on silica gel (180 mL) using petroleum ether−
EtOAc (9:1) as eluant to afford 1.61 g (3.9%) of 1a as a colorless and
essentially odorless oil, identified by comparison with the published
spectroscopic data.17b
Isolation of Serratol (2). A sample of B. serrata resin (10 g) was
cooled in a freezer at −18 °C for 3 h and then powdered and extracted
as described for B. papyrifera, affording a pale yellow oil with a pine
odor (4.9 g). The latter was dissolved in the minimal amount of
petroleum ether and then vacuum-filtered over neutral alumina (15 g,
ratio oil:stationary phase 1:3, elution volume: 100 mL) to remove
acidic constituents. Removal of the solvent gave 1.40 g (14%) of a
colorless oil, which was purified by gravity CC on silica gel using
petroleum ether−EtOAc (9:1) as eluant to afford 250 mg (2.5%) of 2
as a colorless and odorless oil, identified by comparison with the
published spectroscopic data.28 The purity of serratol obtained in this
way was batch-dependent, and, in some cases, presumably because of
the age of the resin sample used, a further purification by flash
chromatography (petroleum ether−EtOAc, 95:5) was necessary to
obtain a sample of suitable purity.
Isolation of Marine Cembranes. A specimen of Sarcophyton sp.
was collected in January 2010 along the coasts of Bunaken Island in
the Bunaken Marine Park of Manado (Indonesia). A frozen voucher
sample (MAN-10-024) has been deposited at the Department of
Pharmacy, University of Naples Federico II. After homogenization, the
organism (98 g, wet weight) was exhaustively extracted, in sequence,
with methanol and chloroform. The extracts were combined and then
partitioned between ethyl acetate (EtOAc) and H2O to obtain an
organic phase (2.20 g), which was chromatographed on a silica gel
column (230−400 mesh), using a gradient solvent system from hexane
to EtOAc and then MeOH. Fractions eluted with n-hexane−EtOAc
(9:1) afforded sarcophytoxide (7, 445 mg) as a pure compound, while
fractions eluted with n-hexane−EtOAc (8:2) were combined and
further subjected to HPLC (eluent: n-hexane−EtOAc, 96:4), affording
sarcophyn (8, 15 mg). These two compounds were identified on the
basis of the comparison between their physical and spectroscopic data
([α]D,
1H and 13C NMR) with those reported in the literature.20,21
Esterification of Incensol with Acyl Chlorides or Anhydrides.
Synthesis of Incensol Acetate (1b) as a Representative. To a
solution of incensol (1a, 100 mg, 0.33 mmol) in pyridine (2 mL) were
added acetic anhydride (2 mL) and 4-dimethylaminopyridne (DMAP,
80 mg, 0.65 mmol, 2 molar equiv). After stirring for 5 h at room
temperature, the reaction was quenched by dilution with water; 2 N
H2SO4 was added and the reaction was extracted with EtOAc. The
organic phase was dried, filtered, and evaporated, and the residue, a
brown oil, was purified by gravity CC on silica gel using petroleum
ether−EtOAc (98:2) as eluant to yield 58 mg (51%) of incensol
acetate (1b).17b Incensol nonanoate (1c), incensol benzoate (1d), and
incensol cinnamate (1f) were prepared in a similar way, in yields of
50%, 16%, and 89%, respectively.
Incensol nonanoate (1c): colorless oil; IR (KBr) νmax 1738, 1457,
1373, 1164, 1105, 1037 cm−1; 1H NMR (CDCl3, 400 MHz) δH 5.17
(2H, overlapped, H-7, H-3), 4.87 (1H, d, J = 10.1 Hz, H-11), 2.30
(2H, overlapped, H2-2′), 2.18 (2H, overlapped, H2-6), 2.10 (2H,
overlapped, H2-5), 2.19 (2H, overlapped, H2-2), 2.00 (2H, overlapped,
H2-9), 1.85 (1H, overlapped, H-15), 1.80−1.60 (4H, overlapped, H-
13, H-14), 1.65 (2H, overlapped, H2-10), 1.60 (2H, overlapped, H2-
3′), 1.59 (3H, s, H3-19), 1.56 (3H, s, H3-14), 1.24 (10H, overlapped,
from H-4′ to 8′), 1.11 (3H, s, H3-20), 0.88 (3H, d, J = 7.1 Hz, H3-16),
0.86 (3H, d, J = 7.1 Hz, H-17) 0.85 (3H, overlapped, H3-9′); 13C
NMR (CDCl3, 125 MHz) δC 173.0 (C-1′), 135.2 (C-4), 133.3 (C-8),
125.2 (C-7), 121.1 (C-3), 89.1 (C-1), 83.0 (C-12), 76.7 (C-11), 38.5
(C-5), 35.8 (C-13), 34.9 (C-15), 34.1 (C-2′), 33.3 (C-9), 32.0 (C-2),
30.4 (C-15), 29.0−23.5 (C-3′ to 8′ not assigned), 28.0 (C-10), 24.8
(C-6), 22.2 (C-20), 18.1 (C-16), 18.0 (C-17), 17.7(C-19), 16.1 (C-
18), 14.9 (C-9′); ESIMS (positive ion) m/z 469 [M + Na]+;
HRESIMS m/z 469.3660 (calcd for C29H50NaO3 469.3658).
Incensol benzoate (1d): colorless oil; IR (KBr) νmax 1716, 1450,
1269, 1175, 1112, 1027 cm−1; 1H NMR (CDCl3, 400 MHz) δH 8.05
(2H, d, J = 7.0 Hz, H-3′, H-7′), 7.56 (1H, t, J = 7.6 Hz, H-5), 7.45
(2H, t, J = 7.6 Hz, H-4′, H-6′), 5.26 (1H, t, J = 6.1 Hz, H-7), 5.23 (1H,
t, J = 6.1 Hz, H-3), 5.12 (1H, d, J = 10.1 Hz, H-11), 2.24 (2H,
overlapped, H2-6), 2.20 (2H, overlapped, H2-2), 2.15 (2H, overlapped,
H2-5), 2.00 (2H, overlapped, H2-9), 1.94 (1H, overlapped, H-15),
1.80−1.60 (4H, overlapped, H-13, H-14), 1.72 (2H, overlapped, H2-
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10), 1.61 (3H, s, H3-19), 1.61 (3H, s, H3-14), 1.24 (3H, s, H3-20), 0.93
(3H, d, J = 7.1 Hz, H3-16), 0.92 (3H, d, J = 7.1 Hz, H3-17);
13C NMR
(CDCl3, 125 MHz) δC 166.6 (C-1′), 135.3 (C-8), 133.3 (C-4), 132.7
(C-5′), 130.7 (C-2′), 129.6 (C-3′, C-7′), 128.3 (C-4′, C-6′), 125.4 (C-
3), 121.1 (C-7), 89.3 (C-1), 83.2 (C-12), 76.7 (C-11), 38.5 (C-5),
35.8 (C-13), 34.9 (C-15), 33.3 (C-9), 32.0 (C-2), 30.4 (C-14), 28.0
(C-10), 24.8 (C-6), 22.2 (C-20), 18.1 (C-16), 18.0 (C-17), 17.7 (C-
19), 16.1 (C-18); ESIMS (positive ion) m/z 433 [M + Na]+;
HRESIMS m/z 433.2725 (calcd for C27H38NaO3 433.2719).
Incensol cinnamate (1f): colorless oil; IR (KBr) νmax 1712, 1639,
1449, 1300, 1163, 1001, 765 cm−1; 1H NMR (CDCl3, 400 MHz) δH
7.69 (1H, d, J = 16.0 Hz, H-3′), 7.53 (2H, overlapped, H-5′, H-9′),
7.38 (2H, overlapped, H-6′, H-8′), 7.36 (1H, overlapped, H-7′), 6.45
(1H, d, J = 16.0 Hz, H-2′), 5.23 (1H, t, J = 6.1 Hz, H-7), 5.20 (1H, t, J
= 6.1 Hz, H-3), 5.01 (1H, d, J = 10.1 Hz, H-11), 2.21 (2H, overlapped,
H2-6), 2.13 (2H, overlapped, H2-5), 2.19 (2H, overlapped, H2-2), 2.00
(2H, overlapped, H2-9), 1.96 (1H, overlapped, H-15), 1.80−1.60 (4H,
overlapped, H-13, H-14), 1.68 (2H, overlapped, H2-10), 1.61 (3H, s,
H3-19), 1.59 (3H, s, H3-14), 1.18 (3H, s, H3-20), 0.93 (3H, d, J = 7.1
Hz, H-16), 0.91 (3H, d, J = 7.1 Hz, H3-17);
13C NMR (CDCl3, 125
MHz) δC 167.2 (C-1′), 144.6 (C-3′), 135.3 (C-4), 134.5 (C-4′), 133.3
(C-8), 130.2 (C-7′), 129.0 (C-5′, C-9′), 128.0 (C-6′, C-8′), 125.4 (C-
7), 121.1 (C-3), 118.6 (C-2′), 89.3 (C-1), 83.2 (C-12), 76.7 (C-11),
38.5 (C-5), 35.8 (C-13), 34.9 (C-15), 33.3 (C-9), 32.0 (C-2), 30.4 (C-
14), 28.0 (C-10), 24.8 (C-6), 22.2 (C-20), 18.1 (C-16), 18.0 (C-17),
17.7 (C-19), 16.1 (C-18). ESIM (positive ion) m/z 459 [M + Na]+;
HRESIMS m/z 469.2871 (calcd for C29H40NaO3 469.2875).
Steglich Esterification of Incensol (1a). Synthesis of Incensol
Phenylacetate (1e). To a solution of incensol (1a, 200 mg, 0.65
mmol) in EtOAc (10 mL) were added sequentially phenylacetic acid
(533 mg, 3.9 mmol, 6 molar equiv), dicyclohexylcarbodiimide (809
mg, 3.9 mmol, 6 molar equiv), and DMAP (476 mg, 3.9 mmol, 6
molar equiv). After stirring at room temperature for 24 h, the solution
was evaporated and the residue was taken up in toluene (10 mL) and
cooled (−18 °C) for 1 h to precipitate dicyclohexylurea and the
unreacted acid. After filtration on a bed of Celite and evaporation, the
residue was purified by gravity CC on silica gel with petroleum ether−
EtOAc (95:5) as eluent to afford 161 mg (58%) of incensol
phenylacetate (1e).
Incensol phenylacetate (1e): colorless oil; IR (KBr) νmax 1731,
1453, 1253, 1132, 1038, 695 cm−1; 1H NMR (CDCl3, 400 MHz) δH
7.26−7.30 (5H, overlapped, from H-4′ to H-8′), 5.13 (1H, overlapped,
H-7), 5.12 (1H, overlapped, H-3), 4.84 (1H, d, J = 10.1 Hz, H-11),
3.60 (2H, s, H2-2′), 2.18 (2H, overlapped, H-6), 2.10 (2H, overlapped,
H-5), 2.19 (2H, overlapped, H2-2), 2.00 (2H, overlapped, H2-9), 1.85
(1H, overlapped, H-15), 1.80−1.60 (4H, overlapped, H-13, H-14),
1.65 (2H, overlapped, H2-10), 1.54 (3H, s, H3-19), 1.53 (3H, s, H3-
14), 1.05 (3H, s, H3-20), 0.88 (3H, d, J = 7.1 Hz, H3-16), 0.86 (3H, d,
J = 7.1 Hz, H3-17);
13C NMR (CDCl3, 125 MHz) δC 171.6 (C-1′),
135.2 (C-4), 134.4 (C-3′), 133.3 (C-8), 129.0 (C-4′, C-8′), 128.0 (C-
5′, C-7′), 127.0 (C-6′), 125.2 (C-7), 121.1 (C-3), 89.1 (C-1), 83.0 (C-
12), 76.7 (C-11), 42.1 (C-2′), 38.5 (C-5), 35.8 (C-13), 34.9 (C-15),
33.3 (C-9), 32.0 (C-2), 30.4 (C-15), 28.0 (C-10), 24.8 (C-6), 22.2 (C-
20), 18.1 (C-16), 18.0 (C-17), 17.7 (C-19), 16.1 (C-18); ESIMS
(positive ion) m/z 447 [M + Na]+; HRESIMS m/z 447.2881 (calcd
for C28H40NaO3 447.2875).
Epoxidation of Incensol (1a). To a cooled (0 °C) solution of
incensol (1a, 100 mg, 0.33 mmol) in EtOAc (5 mL) were added
sequentially NaOAc (62 mg) and m-CPBA (62 mg, 0.36 mmol, 1.1
molar equiv). The course of the reaction was followed by TLC
[(petroleum ether−EtOAc (9:1) as eluant, Rf 1a = 0.42; Rf 3a = 0.28],
and, after 10 min, the reaction was quenched by the addition of 5%
Na2S2O3, diluted with EtOAc, and washed with saturated NaHCO3.
Removal of the solvent left a yellowish oil, which was purified by
gravity CC on silica gel with petroleum ether−EtOAc (9:1) as eluant
to afford 200 mg (63%) of incensol oxide (3a) as white crystals.17b
Epoxidation of Incensol Acetate (1b). The reaction was carried
out as described for incensol, following the reaction course by TLC
[petroleum ether−EtOAc, 9:1, Rf 1b = 0.66; Rf 3b = 0.22; Rf 4 = 0.33)
After workup, the residue was purified by gravity CC on silica gel with
petroleum ether−EtOAc (9:1) as eluant to afford 25 mg (29%) of 7-
epoxyincensol acetate (4)17b and 27 mg (29%) of 3-epoxyincensol
acetate (3b).17b
Oxidation of Incensol. To a solution of incensol (1a, 200 mg,
0.65 mmol) in CH2Cl2 (5 mL) was added pyridinium chlorochromate
(420 mg, 1.9 mmol, 3 molar equiv). After stirring at room temperature
for 5 h, the solution was evaporated and the residue was taken up in
ethyl ether (5 mL), filtered on a bed of Celite, and evaporated. The
residue was purified by gravity CC on silica gel, using petroleum
ether−EtOAc (95:5) as eluent, affording 85 mg (40%) of incensone
(5).
Incensone (5): white powder; mp 72 °C; IR (KBr) νmax 1718, 1444,
1366, 1039, 938, 890 cm−1; 1H NMR (CDCl3, 400 MHz) δH 5.00
(1H, overlapped, H-7), 4.98 (1H, overlapped, H-3), 3.16 (1H, ddd, J =
17.4, 11.2, 2.0 Hz, H-10a), 2.56 (1H, overlapped, H-13a), 2.51 (1H,
overlapped, H-10b), 2.36 (1H, ddd, J = 17.4, 7.4, 2.0 Hz, H-9a), 2.21
(1H, dd, J = 15.7, 6.5 Hz, H-2a), 2.09 (2H, overlapped, H2-5), 2.08
(1H, overlapped, H-9b), 2.03 (2H, overlapped, H2-6), 1.97 (1H,
overlapped, H-2b), 1.90 (1H, overlapped, H-13a), 1.84 (1H,
overlapped, H-13b), 1.86 (1H, overlapped, H-14a), 1.66 (1H,
overlapped, H-14b), 1.57 (3H, s, H3-15), 1.49 (3H, s, H3-14), 1.30
(3H, s, H3-20), 0.96 (3H, d, J = 7.1 Hz, H3-16), 0.91 (3H, d, J = 7.1
Hz, H3-17);
13C NMR (CDCl3, 125 MHz) δC 210.5 (C-11), 134.7 (C-
4), 134.5 (C-8), 125.2 (C-7), 121.4 (C-3), 90.0 (C-1), 87.9 (C-12),
38.5 (C-5), 35.8 (C-13), 34.9 (C-15), 33.3 (C-9), 32.0 (C-2), 30.4 (C-
15), 28.0 (C-10), 24.8 (C-6), 22.2 (C-20), 18.1 (C-16), 18.0 (C-17),
17.7 (C-19), 16.1 (C-18); ESIMS (positive ion) m/z 327 [M + Na]+;
HRESIMS m/z 327.2304 (calcd for C20H32NaO2 327.2300).
Reduction of Incensone (5). To a solution of incensone (5, 50
mg, 0.15 mmol) in dry THF (5 mL) was added an excess of freshly
powdered LiAlH4 (627 mg, 16.5 mmol). After stirring under nitrogen
for 2 h at room temperature, the reaction was worked up by the
addition of EtOAc to quench the excess of LiAlH4, followed by 2 N
H2SO4 to hydrolyze the aluminate salts. Removal of the solvent left a
yellowish oil, which was purified by gravity CC on silica gel with
petroleum ether−EtOAc (9:1) as eluant to afford 24 mg (53%) of 11-
epi-incensol (6) and 13 mg (28%) of incensol (1a).
11-Epi-incensol (6): white powder; mp 69 °C; IR (KBr) νmax 3653,
1469, 1447, 1072, 1039, 889 cm−1; 1H NMR (CDCl3, 400 MHz) δH
5.20 (1H, overlapped, H-7), 5.15 (1H, overlapped, H-3), 3.73 (1H, m,
H-11), 2.25 (2H, overlapped, H2-6), 2.15 (2H, overlapped, H2-5), 2.19
(2H, overlapped, H2-2), 2.00 (2H, overlapped, H2-9), 1.99 (1H,
overlapped, H-15), 1.65−1.78 (4H, overlapped, H-13, H-14), 1.73
(2H, overlapped, H2-10), 1.58 (3H, s, H3-19), 1.58 (3H, s, H3-14),
1.13 (3H, s, H3-20), 0.95 (3H, d, J = 7.1 Hz, H3-16), 0.91 (3H, d, J =
7.1 Hz, H3-17);
13C NMR (CDCl3, 125 MHz) δC 137.6 (C-4), 137.3
(C-8), 122.8 (C-7), 122.8 (C-3), 89.5 (C-1), 86.1 (C-12), 77.2 (C-
11), 40.5 (C-5), 35.7 (C-13), 34.3 (C-15), 33.2 (C-9), 31.0 (C-2),
30.4 (C-15), 28.0 (C-10), 24.8 (C-6), 22.2 (C-20), 18.1 (C-16), 18.0
(C-17), 17.7 (C-19), 15.5 (C-18); ESIMS (positive ion) m/z 329 [M
+ Na]+; HRESIMS m/z 329.2477 (calcd for C20H34NaO2 329.2475).
TRPV3 Activity Experiments. HEK293 (human embryonic
kidney) cells stably overexpressing recombinant rat TRPV3 were
provided by Dr. Heather Bradshaw (Indiana University, USA). They
were grown on 100 mm diameter Petri dishes as monolayers in
minimum essential medium (MEM) supplemented with nonessential
amino acids, 10% fetal bovine serum, and 2 mM glutamine and were
maintained at 5% CO2 at 37 °C. The effect of the substances on
intracellular Ca2+ concentration ([Ca2+]i) was determined by using
Fluo-4 AM, a selective intracellular fluorescent probe for Ca2+. On the
day of the experiment, cells were loaded for 1 h at room temperature
with the methyl ester Fluo-4 AM (4 μM in DMSO containing 0.02%
Pluronic F-127, Invitrogen) in MEM without fetal bovine serum, then
were washed twice in Tyrode’s buffer (145 mM NaCl, 2.5 mM KCl,
1.5 mM CaCl2, 1.2 mM MgCl2, 10 mM D-glucose, and 10 mM
HEPES, pH 7.4), resuspended in the same buffer, and transferred
(about 100 000 cells) to the quartz cuvette of the spectrofluorimeter
(PerkinElmer LS 50B, PerkinElmer Life and Analytical Sciences,
Waltham, MA, USA) under continuous stirring. TRPV3-expressing
HEK293 cells were first sensitized with the structurally unrelated
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agonist 2-aminoethoxydiphenyl borate (100 μM). [Ca2+]i was
determined before and after the addition of various concentrations
of test compounds by measuring cell fluorescence at 25 °C (λEX = 488
nm, λEM = 516 nm). Curve fitting (sigmoidal dose−response variable
slope) and parameter estimation were performed with GraphPad
Prism (GraphPad Software Inc., San Diego, CA, USA). Potency was
expressed as the concentration of test substances exerting a half-
maximal agonist effect (i.e., half-maximal increases in [Ca2+]i) (EC50).
The efficacy of the agonists was determined by normalizing their effect
to the maximum Ca2+ influx effect on [Ca2+]i observed with
application of 4 μM ionomycin (Invitrogen). The values of the effect
on [Ca2+]i in wild-type (i.e., not transfected with any construct)
HEK293 cells were taken as baseline and subtracted from the values
obtained from transfected cells. Antagonist/desensitizing behavior was
evaluated against thymol (100 μM), by adding the test compounds in
a quartz cuvette 5 min before stimulation of cells with agonists. Data
are expressed as the concentration exerting a half-maximal inhibition of
agonist-induced [Ca2+]i elevation (IC50), which was calculated again
using GraphPad Prism software. The effect on [Ca2+]i exerted by
agonist alone was taken as 100%. Dose−response curves were fitted by
a sigmoidal regression with variable slope. All determinations were
performed at least in triplicate. Statistical analysis of the data was
performed by analysis of variance at each point using ANOVA
followed by the Bonferroni’s test.
Luciferase Assays. The origin and characterization of the NIH-
3T3-KBF-Luc and HeLa-STAT3-Luc cell lines have been previously
described.29 The cells were grown at 37 °C and 5% CO2 in
supplemented Dulbecco’s modified Eagle medium containing 10%
heat-inactivated fetal bovine serum, 2 mM glutamine, penicillin (50 U/
mL), and streptomycin (50 μg/mL). For the anti-NF-κB activity,
NIH-3T3-KBF-Luc cells were stimulated with TNFα (20 ng/mL) in
the presence or the absence of the compounds for 6 h. For the anti-
STAT3 activity, HeLa-STAT3-Luc cells were stimulated with INFγ
(20 IU) in the presence or absence of the compounds for 6 h. After
treatment, the cells were washed twice in phosphate buffer saline and
lysed in 25 mM Tris-phosphate buffer (pH 7.8), 8 mM MgCl2, 1 mM
dithiothreitol, 1% Triton X-100, and 7% glycerol for 15 min at room
temperature in a horizontal shaker. After centrifugation, luciferase
activity in the supernatant was measured using an Autolumat LB 9510
(Berthold) in accordance with the instructions of the luciferase assay
kit (Promega, Madison, WI, USA). SC-514, a selective IKK2 inhibitor,
was used as a positive control, and IC50 calculations were performed
using GraphPad Prism (Graph Pad Software). Sample population
means were compared against control population means in an
unpaired two-tailed Student’s t test.
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